MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Arcus Biosciences Inc

Suletud

SektorTervishoid

9.15 -2.97

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

9.1

Max

9.26

Põhinäitajad

By Trading Economics

Sissetulek

-18M

-112M

Müük

2M

28M

Kasumimarginaal

-400

Töötajad

627

EBITDA

-34M

-122M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+176.39% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. aug 2025

Turustatistika

By TradingEconomics

Turukapital

56M

1B

Eelmine avamishind

12.12

Eelmine sulgemishind

9.15

Uudiste sentiment

By Acuity

40%

60%

131 / 376 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Neutral Evidence

Arcus Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

18. juuli 2025, 21:01 UTC

Tulu

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

18. juuli 2025, 20:50 UTC

Market Talk
Tulu

Tech, Media & Telecom Roundup: Market Talk

18. juuli 2025, 20:50 UTC

Market Talk
Tulu

Auto & Transport Roundup: Market Talk

18. juuli 2025, 20:50 UTC

Market Talk
Tulu

Basic Materials Roundup: Market Talk

18. juuli 2025, 20:46 UTC

Tulu

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

18. juuli 2025, 20:39 UTC

Omandamised, ülevõtmised, äriostud

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18. juuli 2025, 20:36 UTC

Tulu

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

18. juuli 2025, 20:16 UTC

Omandamised, ülevõtmised, äriostud

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

18. juuli 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18. juuli 2025, 20:02 UTC

Market Talk

Gold Higher to Close Out Week -- Market Talk

18. juuli 2025, 19:14 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

18. juuli 2025, 19:06 UTC

Market Talk

Oil Futures Snap Two-Week Winning Streak -- Market Talk

18. juuli 2025, 18:24 UTC

Tulu

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

18. juuli 2025, 18:19 UTC

Tulu

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

18. juuli 2025, 18:11 UTC

Omandamised, ülevõtmised, äriostud

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

18. juuli 2025, 18:11 UTC

Tulu

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

18. juuli 2025, 17:35 UTC

Market Talk

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

18. juuli 2025, 16:29 UTC

Market Talk

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

18. juuli 2025, 16:28 UTC

Omandamised, ülevõtmised, äriostud

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18. juuli 2025, 16:22 UTC

Tulu

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

18. juuli 2025, 16:20 UTC

Market Talk
Tulu

Financial Services Roundup: Market Talk

18. juuli 2025, 16:20 UTC

Market Talk
Tulu

Tech, Media & Telecom Roundup: Market Talk

18. juuli 2025, 16:20 UTC

Market Talk
Tulu

Auto & Transport Roundup: Market Talk

18. juuli 2025, 16:20 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Energy & Utilities Roundup: Market Talk

18. juuli 2025, 16:20 UTC

Market Talk
Tulu

Basic Materials Roundup: Market Talk

18. juuli 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18. juuli 2025, 16:04 UTC

Tulu

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

18. juuli 2025, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

18. juuli 2025, 15:58 UTC

Market Talk

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

18. juuli 2025, 15:47 UTC

Market Talk
Tulu

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Arcus Biosciences Inc Prognoos

Hinnasiht

By TipRanks

176.39% tõus

12 kuu keskmine prognoos

Keskmine 25.29 USD  176.39%

Kõrge 46 USD

Madal 12 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Arcus Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

9 ratings

8

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

8.01 / 8.75Toetus ja vastupanu

Lühikene perspektiiv

Neutral Evidence

Keskpikk perspektiiv

Neutral Evidence

Pikk perspektiiv

Weak Bearish Evidence

Sentiment

By Acuity

131 / 376 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.